---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-050856"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:22:50.113309+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics notified of non-compliance with Nasdaq $1.00 bid price rule; 180-day cure period to March 2024

## Summary
- Received deficiency notice on Sep 26, 2023 after 30 consecutive business days of closing bid price below $1.00.
- Must regain compliance by March 25, 2024 by achieving $1.00 close for at least 10 consecutive business days.
- May be eligible for additional 180-day cure period if meeting other Nasdaq listing standards and providing written intent to cure.
- Company will consider all options, including a potential reverse share split, to address the deficiency.

## SEC filing metadata
- accession: 0000950170-23-050856
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/0000950170-23-050856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/itrm-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-050856
- JSON: https://secwatch.observer/filing/0000950170-23-050856.json
- Plain text: https://secwatch.observer/filing/0000950170-23-050856.txt

## Key facts
- Listing & Compliance Notices
  Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: September 26, 2023, Iterum Therapeutics plc (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, (“ Nasdaq ”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasda
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/0000950170-23-050856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.